Motilal Oswal Analyzes Medanta’s Growth Potential
Motilal Oswal Financial Services (MOFSL) believes Medanta, a hospital chain, is a good investment. They’ve given it a “Buy” rating because Medanta is growing quickly and has a clear plan for future expansion. Their analysis suggests the stock could increase significantly.
Key Points
- Medanta is expected to grow quickly thanks to smart planning.
- MOFSL suggests a target price of ₹1,480 per share.
- A stock increase of nearly 17% is anticipated at current levels.
- Noida hospital addresses a local healthcare need.
- Profitability is expected to improve within 1.5 years.
- Strong financial backing supports expansion investments.
Medanta’s new hospital in Noida is important because it helps fill a gap in healthcare services in that area. There aren’t enough hospital beds available, and this new facility can serve a large area, including cities and towns within a 250-kilometer radius. This includes places like Delhi, Uttar Pradesh, and Rajasthan.
The Noida hospital has 226 beds, with 80 specifically for intensive care. Medanta already operates successful hospitals in Gurugram, Lucknow, and Patna. MOFSL believes that the increased use of the Lucknow hospital during the pandemic has made Medanta a well-known brand in North India.
While the Noida hospital isn’t profitable yet, MOFSL thinks it will start making money within 12 to 18 months. They project that Medanta’s overall profits will grow by 16% over the next three years, reaching ₹1,400 crore. They also expect growth in Medanta’s existing hospitals and new hospitals they’re building.
Medanta has a lot of cash – about ₹700 crore – which they can use to build more hospitals and improve the ones they already have. This includes building new hospitals in Mumbai, Delhi, and Guwahati, and also maintaining the existing ones.
Ultimately, investing in Medanta looks promising based on MOFSL’s detailed analysis and strong financial position.
